Last reviewed · How we verify
NCT03977402: TCCP
Total Cancer Care Protocol: A Lifetime Partnership With Patients Who Have or May be at Risk of Having Cancer
trial testing Biological specimen collection in Cancer in 47,500 participants. Currently enrolling.
31 December 2036
Quick facts
| Lead sponsor | New Mexico Cancer Research Alliance |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 47,500 |
| Start date | 27 January 2016 |
| Primary completion | 31 December 2036 |
| Estimated completion | 31 December 2037 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Biological specimen collection
Conditions studied
- Cancer — all drugs for Cancer →
- Cancer Risk — all drugs for Cancer Risk →
Sponsor
New Mexico Cancer Research Alliance — full company profile →
Who can join
18 and older, any sex, with Cancer or Cancer Risk. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The overall objective of this study is to ultimately develop an improved standard of cancer care by facilitating new cancer research, clinical trials, new technology, new informatics solutions, and "personalized medicine" for the University of New Mexico Comprehensive Cancer Center (UNMCCC) and the Oncology Research Information Exchange Network (ORIEN) Consortium of academic medical centers, community hospital systems, and other health care providers. To bring new translational research to the community, the ORIEN consortium has initiated the ORIEN Total Cancer Care Program (TCCP). The TCCP establishes a unique collection of blood, tissue, other biological samples and their associated data (survey data, medical records data, cancer registry data, and other related data) from thousands of patients with cancer or at risk of having cancer. This is not a treatment trial. It is a study designed to create a centralized data and tissue repository.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
An Idealized Clinicogenomic Registry to Engage Underrepresented Populations Using Innovative Technology.
Silva P, Dahlke DV, Smith ML, Charles W, et al · · 2022 · cited 12× · PMID 35629136 · DOI 10.3390/jpm12050713 -
Profiling the molecular and clinical landscape of glioblastoma utilizing the Oncology Research Information Exchange Network brain cancer database.
Demetriou AN, Chow F, Craig DW, Webb MG, et al · · 2024 · cited 9× · PMID 38665799 · DOI 10.1093/noajnl/vdae046 -
Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors.
Wang X, Li T, Eljilany I, Soupir A, et al · · 2025 · cited 6× · PMID 41233329 · DOI 10.1038/s41467-025-65016-3 -
The T Cell Immunoscore as a Reference for Biomarker Development Utilizing Real-World Data from Patients with Advanced Malignancies Treated with Immune Checkpoint Inhibitors.
Eljilany I, Saghand PG, Chen J, Ratan A, et al · · 2023 · cited 6× · PMID 37894280 · DOI 10.3390/cancers15204913 -
Neoadjuvant Intratumoral Plasmid IL-12 Electro-Gene-Transfer and Nivolumab in Patients with Operable, Locoregionally Advanced Melanoma.
Tarhini AA, Eroglu Z, Eljilany I, Zager JS, et al · · 2024 · cited 5× · PMID 39417680 · DOI 10.1158/1078-0432.ccr-24-2768 -
Comparing the rate of immunotherapy treatment change due to toxicity by sex.
Chua KJ, Kronstedt S, Kaldany A, Srivastava A, et al · · 2024 · cited 5× · PMID 38189893 · DOI 10.1002/cnr2.1932 -
Differences in Co-Expression of T Cell Co-Inhibitory and Co-Stimulatory Molecules with PD-1 Across Different Human Cancers.
Tarhini AA, Hedges D, Tan AC, Rodriguez P, et al · · 2024 · cited 2× · PMID 40083977 · DOI 10.29011/2574-710x.10224 -
Differential Infiltration of Key Immune T-Cell Populations Across Malignancies Varying by Immunogenic Potential and the Likelihood of Response to Immunotherapy.
Eljilany I, Coleman S, Tan AC, McCarter MD, et al · · 2024 · cited 2× · PMID 39682743 · DOI 10.3390/cells13231993
Verify or expand the search:
- PubMed search for NCT03977402
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Biological specimen collection
Trials testing the same drug.
- NCT06357845 — Linking Somatic Mutation Rate With Baseline Exposure in East Palestine · NA · recruiting
Other recruiting trials for Cancer
Currently open trials in the same condition.
- NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
- NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
- NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
- NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
- NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting
Other New Mexico Cancer Research Alliance trials
Trials by the same sponsor.
- NCT07436793 — Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial · Phase 2 · not yet recruiting
- NCT06260332 — Physical Activity Intervention for the Improvement of Pain in Young, Hispanic Breast Cancer Survivors · NA · active not recruiting
- NCT06207864 — Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing · NA · recruiting
- NCT05176743 — Food Insecurity in Oncology · NA · completed
- NCT04259762 — Enhancing Cancer Prevention and Control Pathways-Native Health Initiative · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03977402 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by New Mexico Cancer Research Alliance
- Last refreshed: 22 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03977402.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing